↓ Skip to main content

Access to End-of Life Parkinson's Disease Patients Through Patient-Centered Integrated Healthcare

Overview of attention for article published in Frontiers in Neurology, July 2018
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (68th percentile)
  • Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

twitter
8 X users

Citations

dimensions_citation
15 Dimensions

Readers on

mendeley
55 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Access to End-of Life Parkinson's Disease Patients Through Patient-Centered Integrated Healthcare
Published in
Frontiers in Neurology, July 2018
DOI 10.3389/fneur.2018.00627
Pubmed ID
Authors

Carsten Eggers, Richard Dano, Juliane Schill, Gereon R. Fink, Lars Timmermann, Raymond Voltz, Heidrun Golla, Stefan Lorenzl

Abstract

Background: Palliative care in Parkinson's Disease (PD) patients considerably differs from palliative care in oncology patients. Integrated care models are a concept to support patients and improve management of PD symptoms. However, it is not known if the access to PD patients at the end of life can be achieved through integrated care models. Aim: To analyze an integrated model of care for PD patients with the aim to identify if this integrated model of care has access to PD patients at the end of life. Material and Methods: The Cologne Parkinson's network was designed as a randomized, controlled prospective clinical trial in order to increase quality of life of PD patients. This innovative model of care integrated a neurologist in private practice, a movement disorder specialist of the University Hospital and a PD nurse. Mortality rates of PD patients during the study period of 6 months were registered and compared with mortality rates of the general population of Germany according to the Federal Statistical Office of Germany. The retrospective post-hoc analysis was conducted after completion of the initial study at the University Hospital and neurologists' practices in the greater area of Cologne, Germany. Eligible patients had a diagnosis of idiopathic PD and were aged 25-85 years. Results: Parkinson's Disease patients in this trial had an even slightly lower mortality rate as the general population (1.66 v. 2.1%). These results are contradictory and speak for a substantial proportion of late-stage disease patients, who have not been adequately included in this study or have been better treated within this trial. The mean disease duration of patients in this study was around 6 years which resembles the lower range of the mean disease duration at death of PD patients in general. Conclusions: The results of our post-hoc analysis show, that accessing PD patients in the last phase of their disease is extremely difficult and nearly fails in spite of an integrated care approach. Reasons for poor access and loss of follow-up at the end of life have to be identified and care models for PD patients until the end of life should be developed urgently.

X Demographics

X Demographics

The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 55 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 55 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 8 15%
Student > Master 4 7%
Student > Ph. D. Student 3 5%
Unspecified 2 4%
Student > Postgraduate 2 4%
Other 3 5%
Unknown 33 60%
Readers by discipline Count As %
Nursing and Health Professions 8 15%
Medicine and Dentistry 5 9%
Neuroscience 3 5%
Unspecified 2 4%
Social Sciences 2 4%
Other 5 9%
Unknown 30 55%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 August 2018.
All research outputs
#6,332,585
of 24,089,711 outputs
Outputs from Frontiers in Neurology
#4,221
of 13,134 outputs
Outputs of similar age
#104,348
of 333,558 outputs
Outputs of similar age from Frontiers in Neurology
#78
of 318 outputs
Altmetric has tracked 24,089,711 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 13,134 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.4. This one has gotten more attention than average, scoring higher than 67% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 333,558 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 318 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.